April 22, 2010 – Broadening its product scope into the peripheral artery disease market, Medtronic today received U.S. Food and Drug Administration (FDA) clearance for the Complete SE Vascular...
April 21, 2010 – A stent that captures endothelial progenitor cells is now combined with thin cobalt chromium stent struts with a low profile for greater flexibility and deliverability. The Genous...
April 21, 2010 – More than 100,000 amputations are performed each year in the United States on patients with critical limb ischemia (CLI), the most severe form of peripheral arterial disease (PAD...
April 13, 2010 – More than 300 patients in Europe have been enrolled in a real-world study to assess the effectiveness of a coronary bifurcation stent. Enrollment was completed last week in E-...
April 5, 2010 – Patient enrollment was recently completed in the Small Vessel and Long Lesion trials of the PLATINUM clinical program. It is designed to compare the platinum chromium Promus...
March 30, 2010 – A new coronary stent recently launched in Europe is designed to gain easier access to distal lesions and help restore the artery's natural form.
March 26, 2010 – Nearly 14 percent of Medicare beneficiaries admitted with a primary diagnosis of ST-elevated myocardial infarction (STEMI) undergo multivessel primary percutaneous coronary...
Final five-year results from the ENDEAVOR III trial, comparing the Endeavor Zotarolimus-Eluting Coronary Stent to the Cypher Sirolimus-Eluting Coronary Stent, showed Endeavor had lower long-term...
March 24, 2010 – A team of Mayo Clinic researchers found that cardiac rehabilitation is associated with significantly reduced mortality rates for patients who receive coronary stents. The findings...
March 15, 2010 — Results from the PERSEUS clinical program demonstrate positive safety and efficacy outcomes in workhorse lesions for a new platinum chromium stent system.
March 15, 2010 — Investigators reported the long-term follow-up of the largest randomized comparison between the two drug-eluting stents during the American College of Cardiology annual meeting...
March 17, 2010 – New data released at the American College of Cardiology Scientific Session this week showed continued positive clinical results for the Xience V everolimus-eluting coronary stent...
March 5, 2010 – Experts will lead an evening symposium during ACC 2010 that will cover the latest clinical and experimental breakthroughs in the percutaneous treatment of coronary artery disease....
March 1, 2010 – Surgery and stenting to open blocked neck arteries proved similar in overall long-term safety and efficacy, but showed differences in stroke and heart attack in the weeks following...
February 2, 2010 – Data published in EuroIntervention (EuroIntervention, 2010; 5:698-702) demonstrate good safety and efficacy, low target vessel revascularization (TVR) and no late stent...
February 1, 2010 – Three patent disputes between Boston Scientific Corp. and Johnson & Johnson (J&J) were settled today with Boston paying $1.7 billion.
January 27, 2010 – New 6, 7 and 8 mm diameters of the Maris Plus self-expanding peripheral stent system, were launched today in Europe for interventions involving the superficial femoral arteries...
January 25, 2010 – Expanding its peripheral vascular disease product offerings, Medtronic Inc. today signed an agreement to acquire Invatec and two affiliated companies.
January 25, 2010 – Trials for a stent that attracts endothelial progenitor cells show positive results in patients with bifurcation lesions and those with non-ST-segment elevation acute coronary...
January 25, 2010 – Direct stenting of the carotid arteries is a feasible technique and is not inferior to predilation, according to a new study published in the International Journal of Cardiology...
January 8, 2010 – Japanese regulatory officials this week cleared the XIENCE V Everolimus-Eluting Coronary Stent. Abbott said it plans to launch sales in Japan in the coming weeks, immediately...
January 7, 2010 – Anti-platelet treat with Effient (prasugrel) compared with Plavix (clopidogrel) was more cost effective, according to results from a health economic substudy of the TRITON-TIMI...
January 5, 2010 – In vivo and in vitro data released yesterday shows a new bioresorbable stent platform allows for complete endothelialization with little inflammation after one month.
January 4, 2010 – The first patient was enrolled the TAXUS Liberte arm of the Dual Anti-Platelet Therapy (DAPT) Study, evaluating the TAXUS Liberté stent in combination with a dual anti-platelet...
December 8, 2009 – The first live U.K. cases involving Cappella’s self-expanding Sideguard Coronary Sidebranch Stent and delivery system were recently performed at PCI Live 2009 with the second...
November 18, 2009 – New, joint guidelines from the American College of Cardiology (ACC), the American Heart Association (AHA) and the Society for Cardiovascular Angiography and Interventions (SCAI...
November 17, 2009 – Following positive three-year data from the first 30 patients treated with a fully bioabsorbable drug-eluting coronary stent, Abbott is initiating a large-scale trial with...
November 10, 2009 – The latest data from seven studies focused on the treatment of peripheral arterial disease (PAD) were presented in the late-breaking trials session of the Vascular...
November 10, 2009 – Clinically, stent fracture has been reported in 1-2 percent of patients after drug-eluting stent (DES) implantation, but researchers at the CVPath Institute Gaithersburg, Md....
November 3, 2009 – Abbott yesterday said both the XIENCE PRIME Everolimus-Eluting Coronary Stent System and the XIENCE V Everolimus-Eluting Coronary Stent System have received additional new CE...
November 3, 2009 – The FDA said Boston Scientific recently changed the name of the company's Liberté Bare-Metal coronary stent to VeriFLEX, after reports that Liberté Bare-Metal stents were...
October 27, 2009 – Interim six-month clinical results on the use of the FlexStent Femoropopliteal Self Expanding Stent System in the Superficial Femoral Artery were presented today at the VIVA...
October 27, 2009 – Invatec today said it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Mo.Ma Ultra Proximal Cerebral Protection Device for use during...
October 21, 2009 – Cook Medical is introducing six new products in parallel to provide better treatment options to treat peripheral arterial disease (PAD), including new microwires, stents and...
October 21, 2009 – Raydiance Corp., developer of the world’s first commercial-grade ultrafast laser, said today it made a major breakthrough in manufacturing a wide variety of bioabsorbable...
October 14, 2009 – Medtronic Inc. yesterday initiated a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent (DES)...
October 6, 2009 – The Harvard Clinical Research Institute (HCRI) said last week the first patients are enrolled in the DAPT Study, marking the official initiation of the four-year clinical trial...
October 6, 2009 - Boston Scientific Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its WallFlex Biliary RX fully and partially covered...
October 6, 2009 – Boston Scientific Corp. released data during TCT 2009 from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS Liberté...
October 1, 2009 – Flexible Stenting Solutions Inc. (FSS) said this week it received conditional investigational device exemption (IDE) approval from the FDA for its FlexStent Femoropopliteal Self-...
October 1, 2009 – The six-month clinical outcome of Sahajanand Medical Technologies Supralimus Sirolimus-Eluting Stent with a bioabsorbable polymer was highlighted by the company at TCT 2009.
September 30, 2009 – Invatec this week at the European CIRSE 2009 conference launched its latest self-expanding peripheral stent system, Maris Plus, which has a “lesion-specific” design with...
September 30, 2009 – New clinical data released at TCT 2009 last week showed strong and sustained efficacy and safety of the Resolute Zotarolimus-Eluting Coronary Stent from Medtronic Inc. in long...
September 29, 2009 – Among the biggest news to come out of TCT 2009 last week was the late-breaking data from the SPIRIT IV trial, which showed Abbott's XIENCE V Everolimus-Eluting Coronary Stent...
September 29, 2009 – Cordis Corp. and Boston Scientific announced late today they reached an agreement to resolve several pending lawsuits over intellectual property related to drug-eluting stent...
September 29, 2009 – Elixir Medical Corp. last week at TCT 2009 announced positive results from three multicenter first-in-man studies of its novolimus and myolimus-eluting coronary stent systems...
September 29, 2009 – Boston Scientific Corp. Sept. 25 announced two-year follow-up data from the HORIZONS-AMI trial, is designed to determine the safety and efficacy of the TAXUS Express2...
September 29, 2009 – At six months, patients receiving the NEVO Sirolimus-Eluting Coronary Stent reported significantly less chest pain than those receiving the TAXUS Liberte stent, and patients...
September 21, 2009 — Boston Scientific Corp. today welcomed three-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety of the Company's portfolio...
September 22, 2009 – Cordis Corp. has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER Sirolimus-Eluting Coronary Stent – the 2.25 mm...
September 18, 2009 – Boston Scientific today said it completed patient enrollment in the workhorse portion of its PLATINUM clinical program, a global, randomized, pivotal controlled trial designed...
September 18, 2009 – Following the recent CE mark certification of the vProtect Luminal Shield, the novel self-expanding coronary stent system will be the focus of scientific presentations and...
September 18, 2009 ¬– Abbott has announced the company's schedule of key news announcements and events during the Transcatheter Cardiovascular Therapeutics (TCT) 2009 conference in San Francisco,...
September 17, 2009 – Boston Scientific Corp. announced its schedule of the company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) 21st annual...
September 17, 2009 – Elixir Medical Corp. said today its stent systems using bioabsorbable polymers will be featured in multiple sessions at the 21st annual Transcatheter Cardiovascular...
September 15, 2009 – Tryton Medical Inc. said today its Tryton Side Branch Stent has been used in 250 procedures to treat atherosclerotic lesions at bifurcations in patients with heart disease.
September 14, 2009 – OrbusNeich's Genous Bio-engineered R stent is feasible and safe in patients who need coronary revascularization before undeferrable noncardiac surgery and have to discontinue...
Sept. 14, 2009 – Abbott said today the Chinese State Food and Drug Administration (SFDA) has approved the XIENCE V Everolimus-Eluting Coronary Stent System for the treatment of coronary artery...
Gregg W. Stone, M.D., offered a preview Sept. 10 of some of the key, late-breaking clinical trials and trends in interventional cardiology that will be presented during the Transcatheter...
September 3, 2009 – Abbott said last week it received approval from Health Canada for the XIENCE V Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease (CAD).
September 2, 2009 – Abbott announced Monday at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME Everolimus-Eluting Coronary Stent System...
September 1, 2009 – Cordis Corp. said first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take...
August 31, 2009 – IDEV Technologies Inc. announced last week the first patient was enrolled in the company's FDA-approved multicenter clinical trial of its self-expanding SUPERA stent for the...
August 13, 2009 – Abbott today announced the expansion of the company's XIENCE V USA post-approval study designed to evaluate the safety and effectiveness of the company's XIENCE V Everolimus-...
August 11, 2009 – Physicians in the United Kingdom yesterday completed patient implants using the first CE mark approved drug-eluting stent designed specifically to treat severe peripheral artery...
July 29, 2009 – Medtronic Inc. said earlier this week it has reached a settlement with Abbott Laboratories over intellectual property litigation regarding stent design and stent delivery systems...
